Pythium insidiosum: In vitro oomicidal evaluation of telithromycin and interactions with azithromycin and amorolfine hydrochloride

IF 2.2 4区医学 Q3 MYCOLOGY

Journal de mycologie medicale Pub Date : 2024-01-11 DOI:10.1016/j.mycmed.2024.101460

Lara Baccarin Ianiski , Aline Fontanella Maciel , Ana Carolina Nolasco Colla , Caroline Quintana Braga , Luis Antônio Sangioni , Mahendra Pal , Daniela Isabel Brayer Pereira , Janio Morais Santurio , Sônia de Avila Botton

{"title":"Pythium insidiosum: In vitro oomicidal evaluation of telithromycin and interactions with azithromycin and amorolfine hydrochloride","authors":"Lara Baccarin Ianiski , Aline Fontanella Maciel , Ana Carolina Nolasco Colla , Caroline Quintana Braga , Luis Antônio Sangioni , Mahendra Pal , Daniela Isabel Brayer Pereira , Janio Morais Santurio , Sônia de Avila Botton","doi":"10.1016/j.mycmed.2024.101460","DOIUrl":null,"url":null,"abstract":"<div>This study evaluated the repositioning of the ketolide antibacterial telithromycin (TLT) against the oomycete Pythium insidiosum and verified the combination of TLT and the antimicrobials azithromycin (AZM) and amorolfine hydrochloride (AMR), which have known anti-P. insidiosum activity. Susceptibility tests of P. insidiosum isolates (n = 20) against the drugs were carried out according to CLSI protocol M38-A2, and their combinations were evaluated using the checkerboard microdilution method. The minimum inhibitory concentrations were 0.5–4 µg/mL for TLT, 2–32 µg/mL for AZM, and 16–64 µg/mL for AMR. For the TLT+AZM combination, 52.75 % of interactions were indifferent, 43.44 % were antagonistic, and 9.70 % were synergistic. As for interactions of the TLT+AMR combination, 60.43 % were indifferent, 39.12 % were antagonistic, and 10.44 % synergistic interactions. This study is the first to evaluate the repositioning of the antibacterial TLT against mammalian pathogenic oomycetes, and our results show that its isolated action is superior to its combinations with either AZM or AMR. Therefore, we recommend including TLT in future research to evaluate therapeutic approaches in different clinical forms of human and animal pythiosis.</div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal de mycologie medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1156523324000015","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This study evaluated the repositioning of the ketolide antibacterial telithromycin (TLT) against the oomycete Pythium insidiosum and verified the combination of TLT and the antimicrobials azithromycin (AZM) and amorolfine hydrochloride (AMR), which have known anti-P. insidiosum activity. Susceptibility tests of P. insidiosum isolates (n = 20) against the drugs were carried out according to CLSI protocol M38-A2, and their combinations were evaluated using the checkerboard microdilution method. The minimum inhibitory concentrations were 0.5–4 µg/mL for TLT, 2–32 µg/mL for AZM, and 16–64 µg/mL for AMR. For the TLT+AZM combination, 52.75 % of interactions were indifferent, 43.44 % were antagonistic, and 9.70 % were synergistic. As for interactions of the TLT+AMR combination, 60.43 % were indifferent, 39.12 % were antagonistic, and 10.44 % synergistic interactions. This study is the first to evaluate the repositioning of the antibacterial TLT against mammalian pathogenic oomycetes, and our results show that its isolated action is superior to its combinations with either AZM or AMR. Therefore, we recommend including TLT in future research to evaluate therapeutic approaches in different clinical forms of human and animal pythiosis.

查看原文本刊更多论文

内生疽脓菌：泰利霉素的体外杀卵评价以及与阿奇霉素和盐酸阿莫罗芬的相互作用

本研究评估了酮烷类抗菌药泰利霉素（TLT）对卵菌类内生脓胞癣菌的重新定位，并验证了 TLT 与已知具有抗内生脓胞癣菌活性的抗菌药阿奇霉素（AZM）和盐酸阿莫罗芬（AMR）的组合。根据 CLSI M38-A2 规程，对 P. insidiosum 分离物（n = 20）进行了药物敏感性试验，并使用棋盘微量稀释法评估了药物组合。TLT的最小抑菌浓度为0.5-4 µg/mL，AZM为2-32 µg/mL，AMR为16-64 µg/mL。对于 TLT+AZM 组合，52.75% 的相互作用是无影响的，43.44% 是拮抗的，9.70% 是协同的。至于TLT+AMR组合的相互作用，60.43%为无所谓，39.12%为拮抗作用，10.44%为协同作用。这项研究首次评估了抗菌剂 TLT 对哺乳动物致病性卵菌的重新定位，我们的结果表明，TLT 的单独作用优于其与 AZM 或 AMR 的组合。因此，我们建议将 TLT 纳入未来的研究中，以评估不同临床形式的人类和动物脓毒血症的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal de mycologie medicale 医学-真菌学

CiteScore

5.10

自引率

2.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal de Mycologie Medicale / Journal of Medical Mycology (JMM) publishes in English works dealing with human and animal mycology. The subjects treated are focused in particular on clinical, diagnostic, epidemiological, immunological, medical, pathological, preventive or therapeutic aspects of mycoses. Also covered are basic aspects linked primarily with morphology (electronic and photonic microscopy), physiology, biochemistry, cellular and molecular biology, immunochemistry, genetics, taxonomy or phylogeny of pathogenic or opportunistic fungi and actinomycetes in humans or animals. Studies of natural products showing inhibitory activity against pathogenic fungi cannot be considered without chemical characterization and identification of the compounds responsible for the inhibitory activity. JMM publishes (guest) editorials, original articles, reviews (and minireviews), case reports, technical notes, letters to the editor and information. Only clinical cases with real originality (new species, new clinical present action, new geographical localization, etc.), and fully documented (identification methods, results, etc.), will be considered. Under no circumstances does the journal guarantee publication before the editorial board makes its final decision. The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.